Xenotransplantation And Animal Rights

Franklin Hoke's interesting article about strides in technologies that may soon make xenotransplantation clinically viable ("Biotech Companies Set To Profit From Animal Organ Transplants," The Scientist, Oct. 16, 1995, page 1) was marred by the inclusion of the predictable complaints and criticisms of animal-rights groups. Spokespersons for these groups have nothing of value to say about science in any form, since they know little or nothing about it, or they conveniently subjugate their scien

Written bySharon Russell
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Spokespersons for these groups have nothing of value to say about science in any form, since they know little or nothing about it, or they conveniently subjugate their scientific knowledge to correspond with their fuzzy, sentimental pseudophilosophy demanding no animal use for any reason. This blanket statement includes those who really should know better, by virtue of having had medical or veterinary training. The time has come for responsible media to stop fawning on these neo-Luddite organizations and give them the treatment they deserve-ignore them.

Otherwise, in order to be consistent, The Scientist should include statements from creationists in every article having to do with evolution, the age of the universe, and so forth, as well as the insights of members of the Flat Earth Society each time you publish something about Earth or space travel and exploration.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies